For Investors

Close

Incyte International Locations

NORTH AMERICA—
HEADQUARTERS

FINLAND

JAPAN

SWEDEN

EUROPE—
HEADQUARTERS

FRANCE

THE NETHERLANDS

SWITZERLAND

AUSTRIA

GERMANY

NORWAY

UNITED KINGDOM

DENMARK

ITALY

SPAIN

Home > Investor Relations

Investor Relations

Overview

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

Events & Presentations

Upcoming

Tuesday June 9, 2020 at 8:00 AM EDT
Goldman Sachs 41st Annual Global Healthcare Conference

View All Events

Prior

Monday April 6, 2020 at 8:00 AM EDT
Ruxolitinib Cream: Phase 3 Data in Atopic Dermatitis

View All Events

Press Releases

May 21, 2020

Incyte to Present at Upcoming Investor Conference


May 20, 2020

Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab


May 14, 2020

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings


View All Releases

Investor Contacts

Michael Booth D.Phil
Division VP, Investor Relations & Corporate Responsibility
Phone: 302.498.5914
mbooth@incyte.com

Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility
Phone: 302.498.6141
layala@incyte.com

Christine Chiou
Senior Director, Investor Relations
Phone: 302.274.4773
cchiou@incyte.com

Copyright West LLC. Minimum 15 minutes delayed.

Annual Reports

Quarterly Reports

RSS Feeds


All Press Releases

All Events

All SEC Filings